Cardiac events following JYNNEOS vaccination for prevention of Mpox

The incidence of cardiac adverse events following JYNNEOS vaccination for prevention of mpox is unknown, however the Advisory Committee on Immunization Practices states that people with underlying cardiac risk factors should be counseled about the theoretical risk for myopericarditis following vacci...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2023-05, Vol.41 (22), p.3410-3412
Main Authors: Sharff, Katie A., Tandy, Thomas K., Lewis, Paul F., Johnson, Eric S.
Format: Article
Language:English
Subjects:
Adverse events
Cardiovascular disease
Cohort analysis
Drug dosages
Electronic health records
Electronic medical records
Emergency medical care
FDA approval
Heart
Humans
Immunization
Infections
Mpox
Mpox (monkeypox) - prevention & control
Myocarditis
Myocarditis - etiology
Patients
Pericarditis
Prevention
Retrospective Studies
Risk factors
Smallpox
Smallpox Vaccine - adverse effects
Teenagers
Vaccination
Vaccines
Vaccines, Attenuated - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c393t-688973c3a393962afabfaef6dcaa3438784889b5b3ded8aeb2e35ed9cd99ebdf3
cites cdi_FETCH-LOGICAL-c393t-688973c3a393962afabfaef6dcaa3438784889b5b3ded8aeb2e35ed9cd99ebdf3
container_end_page 3412
container_issue 22
container_start_page 3410
container_title Vaccine
container_volume 41
creator Sharff, Katie A.
Tandy, Thomas K.
Lewis, Paul F.
Johnson, Eric S.
description The incidence of cardiac adverse events following JYNNEOS vaccination for prevention of mpox is unknown, however the Advisory Committee on Immunization Practices states that people with underlying cardiac risk factors should be counseled about the theoretical risk for myopericarditis following vaccination. We conducted a retrospective cohort study of 2,126 patients who were vaccinated with at least 1 dose of JYNNEOS vaccine and searched the Kaiser Permanente Northwest databases, including the electronic health record, to evaluate for cardiac adverse events of special interest (AESI). After physician adjudication, there were 10 confirmed cardiac AESI for an incidence of 3.1 per 1000 doses (exact 95% CI, 1.5 to 5.7), however none of these events could be directly attributed to vaccination. This retrospective cohort study of JYNNEOS vaccination for prevention of mpox identified 10 cardiac events that all had alternative explanations; and no hospitalizations or serious adverse outcomes were attributed to vaccination.
doi_str_mv 10.1016/j.vaccine.2023.04.052
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2807917003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X23004668</els_id><sourcerecordid>2813885267</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-688973c3a393962afabfaef6dcaa3438784889b5b3ded8aeb2e35ed9cd99ebdf3</originalsourceid><addsrcrecordid>eNqFkMlOwzAQQC0EomX5BFAkLlwSvMSJc0KoYhXQAyDByXLsCXKVxsVOC_w9Li0cuHAajebN9hA6IDgjmBQnk2yhtLYdZBRTluE8w5xuoCERJUspJ2ITDTEt8jQn-HmAdkKYYIw5I9U2GrCSkBJzPkSjkfLGKp3AAro-JI1rW_duu9fk5uX-_nz8kKzWqN66LlZ9MvPf6DJ1TXI3cx97aKtRbYD9ddxFTxfnj6Or9HZ8eT06u001q1ifFkJUJdNMxawqqGpU3ShoCqOVYjkTpcgjUfOaGTBCQU2BcTCVNlUFtWnYLjpezZ159zaH0MupDRraVnXg5kFSgcsq_oVZRI_-oBM39128LlKECcFpUUaKryjtXQgeGjnzdqr8pyRYLi3LiVxblkvLEucyWo59h-vp83oK5rfrR2sETlcARB0LC14GbaHTYKwH3Uvj7D8rvgBAlZBF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2813885267</pqid></control><display><type>article</type><title>Cardiac events following JYNNEOS vaccination for prevention of Mpox</title><source>ScienceDirect Freedom Collection</source><creator>Sharff, Katie A. ; Tandy, Thomas K. ; Lewis, Paul F. ; Johnson, Eric S.</creator><creatorcontrib>Sharff, Katie A. ; Tandy, Thomas K. ; Lewis, Paul F. ; Johnson, Eric S.</creatorcontrib><description>The incidence of cardiac adverse events following JYNNEOS vaccination for prevention of mpox is unknown, however the Advisory Committee on Immunization Practices states that people with underlying cardiac risk factors should be counseled about the theoretical risk for myopericarditis following vaccination. We conducted a retrospective cohort study of 2,126 patients who were vaccinated with at least 1 dose of JYNNEOS vaccine and searched the Kaiser Permanente Northwest databases, including the electronic health record, to evaluate for cardiac adverse events of special interest (AESI). After physician adjudication, there were 10 confirmed cardiac AESI for an incidence of 3.1 per 1000 doses (exact 95% CI, 1.5 to 5.7), however none of these events could be directly attributed to vaccination. This retrospective cohort study of JYNNEOS vaccination for prevention of mpox identified 10 cardiac events that all had alternative explanations; and no hospitalizations or serious adverse outcomes were attributed to vaccination.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2023.04.052</identifier><identifier>PMID: 37117055</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adverse events ; Cardiovascular disease ; Cohort analysis ; Drug dosages ; Electronic health records ; Electronic medical records ; Emergency medical care ; FDA approval ; Heart ; Humans ; Immunization ; Infections ; Mpox ; Mpox (monkeypox) - prevention &amp; control ; Myocarditis ; Myocarditis - etiology ; Patients ; Pericarditis ; Prevention ; Retrospective Studies ; Risk factors ; Smallpox ; Smallpox Vaccine - adverse effects ; Teenagers ; Vaccination ; Vaccines ; Vaccines, Attenuated - adverse effects</subject><ispartof>Vaccine, 2023-05, Vol.41 (22), p.3410-3412</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-688973c3a393962afabfaef6dcaa3438784889b5b3ded8aeb2e35ed9cd99ebdf3</citedby><cites>FETCH-LOGICAL-c393t-688973c3a393962afabfaef6dcaa3438784889b5b3ded8aeb2e35ed9cd99ebdf3</cites><orcidid>0000-0001-5111-6810</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37117055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharff, Katie A.</creatorcontrib><creatorcontrib>Tandy, Thomas K.</creatorcontrib><creatorcontrib>Lewis, Paul F.</creatorcontrib><creatorcontrib>Johnson, Eric S.</creatorcontrib><title>Cardiac events following JYNNEOS vaccination for prevention of Mpox</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>The incidence of cardiac adverse events following JYNNEOS vaccination for prevention of mpox is unknown, however the Advisory Committee on Immunization Practices states that people with underlying cardiac risk factors should be counseled about the theoretical risk for myopericarditis following vaccination. We conducted a retrospective cohort study of 2,126 patients who were vaccinated with at least 1 dose of JYNNEOS vaccine and searched the Kaiser Permanente Northwest databases, including the electronic health record, to evaluate for cardiac adverse events of special interest (AESI). After physician adjudication, there were 10 confirmed cardiac AESI for an incidence of 3.1 per 1000 doses (exact 95% CI, 1.5 to 5.7), however none of these events could be directly attributed to vaccination. This retrospective cohort study of JYNNEOS vaccination for prevention of mpox identified 10 cardiac events that all had alternative explanations; and no hospitalizations or serious adverse outcomes were attributed to vaccination.</description><subject>Adverse events</subject><subject>Cardiovascular disease</subject><subject>Cohort analysis</subject><subject>Drug dosages</subject><subject>Electronic health records</subject><subject>Electronic medical records</subject><subject>Emergency medical care</subject><subject>FDA approval</subject><subject>Heart</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Mpox</subject><subject>Mpox (monkeypox) - prevention &amp; control</subject><subject>Myocarditis</subject><subject>Myocarditis - etiology</subject><subject>Patients</subject><subject>Pericarditis</subject><subject>Prevention</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Smallpox</subject><subject>Smallpox Vaccine - adverse effects</subject><subject>Teenagers</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated - adverse effects</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkMlOwzAQQC0EomX5BFAkLlwSvMSJc0KoYhXQAyDByXLsCXKVxsVOC_w9Li0cuHAajebN9hA6IDgjmBQnk2yhtLYdZBRTluE8w5xuoCERJUspJ2ITDTEt8jQn-HmAdkKYYIw5I9U2GrCSkBJzPkSjkfLGKp3AAro-JI1rW_duu9fk5uX-_nz8kKzWqN66LlZ9MvPf6DJ1TXI3cx97aKtRbYD9ddxFTxfnj6Or9HZ8eT06u001q1ifFkJUJdNMxawqqGpU3ShoCqOVYjkTpcgjUfOaGTBCQU2BcTCVNlUFtWnYLjpezZ159zaH0MupDRraVnXg5kFSgcsq_oVZRI_-oBM39128LlKECcFpUUaKryjtXQgeGjnzdqr8pyRYLi3LiVxblkvLEucyWo59h-vp83oK5rfrR2sETlcARB0LC14GbaHTYKwH3Uvj7D8rvgBAlZBF</recordid><startdate>20230522</startdate><enddate>20230522</enddate><creator>Sharff, Katie A.</creator><creator>Tandy, Thomas K.</creator><creator>Lewis, Paul F.</creator><creator>Johnson, Eric S.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5111-6810</orcidid></search><sort><creationdate>20230522</creationdate><title>Cardiac events following JYNNEOS vaccination for prevention of Mpox</title><author>Sharff, Katie A. ; Tandy, Thomas K. ; Lewis, Paul F. ; Johnson, Eric S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-688973c3a393962afabfaef6dcaa3438784889b5b3ded8aeb2e35ed9cd99ebdf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse events</topic><topic>Cardiovascular disease</topic><topic>Cohort analysis</topic><topic>Drug dosages</topic><topic>Electronic health records</topic><topic>Electronic medical records</topic><topic>Emergency medical care</topic><topic>FDA approval</topic><topic>Heart</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Mpox</topic><topic>Mpox (monkeypox) - prevention &amp; control</topic><topic>Myocarditis</topic><topic>Myocarditis - etiology</topic><topic>Patients</topic><topic>Pericarditis</topic><topic>Prevention</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Smallpox</topic><topic>Smallpox Vaccine - adverse effects</topic><topic>Teenagers</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharff, Katie A.</creatorcontrib><creatorcontrib>Tandy, Thomas K.</creatorcontrib><creatorcontrib>Lewis, Paul F.</creatorcontrib><creatorcontrib>Johnson, Eric S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep (ProQuest)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharff, Katie A.</au><au>Tandy, Thomas K.</au><au>Lewis, Paul F.</au><au>Johnson, Eric S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiac events following JYNNEOS vaccination for prevention of Mpox</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2023-05-22</date><risdate>2023</risdate><volume>41</volume><issue>22</issue><spage>3410</spage><epage>3412</epage><pages>3410-3412</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>The incidence of cardiac adverse events following JYNNEOS vaccination for prevention of mpox is unknown, however the Advisory Committee on Immunization Practices states that people with underlying cardiac risk factors should be counseled about the theoretical risk for myopericarditis following vaccination. We conducted a retrospective cohort study of 2,126 patients who were vaccinated with at least 1 dose of JYNNEOS vaccine and searched the Kaiser Permanente Northwest databases, including the electronic health record, to evaluate for cardiac adverse events of special interest (AESI). After physician adjudication, there were 10 confirmed cardiac AESI for an incidence of 3.1 per 1000 doses (exact 95% CI, 1.5 to 5.7), however none of these events could be directly attributed to vaccination. This retrospective cohort study of JYNNEOS vaccination for prevention of mpox identified 10 cardiac events that all had alternative explanations; and no hospitalizations or serious adverse outcomes were attributed to vaccination.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>37117055</pmid><doi>10.1016/j.vaccine.2023.04.052</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-5111-6810</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2023-05, Vol.41 (22), p.3410-3412
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_2807917003
source ScienceDirect Freedom Collection
subjects Adverse events
Cardiovascular disease
Cohort analysis
Drug dosages
Electronic health records
Electronic medical records
Emergency medical care
FDA approval
Heart
Humans
Immunization
Infections
Mpox
Mpox (monkeypox) - prevention & control
Myocarditis
Myocarditis - etiology
Patients
Pericarditis
Prevention
Retrospective Studies
Risk factors
Smallpox
Smallpox Vaccine - adverse effects
Teenagers
Vaccination
Vaccines
Vaccines, Attenuated - adverse effects
title Cardiac events following JYNNEOS vaccination for prevention of Mpox
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A12%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiac%20events%20following%20JYNNEOS%20vaccination%20for%20prevention%20of%20Mpox&rft.jtitle=Vaccine&rft.au=Sharff,%20Katie%20A.&rft.date=2023-05-22&rft.volume=41&rft.issue=22&rft.spage=3410&rft.epage=3412&rft.pages=3410-3412&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2023.04.052&rft_dat=%3Cproquest_cross%3E2813885267%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-688973c3a393962afabfaef6dcaa3438784889b5b3ded8aeb2e35ed9cd99ebdf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2813885267&rft_id=info:pmid/37117055&rfr_iscdi=true